| scholarly article | Q13442814 |
| P2093 | author name string | Damien B Ready | |
| Melanie J Patterson | |||
| Gregory K Potts | |||
| Stephanie M Jensen | |||
| P2860 | cites work | A Mechanistic Model for Predicting Cell Surface Presentation of Competing Peptides by MHC Class I Molecules | Q59356427 |
| Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1 | Q89187704 | ||
| PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer | Q37065079 | ||
| Two-headed PROTAC: an effective new tool for targeted protein degradation | Q37367308 | ||
| MHC class I-associated peptides derive from selective regions of the human genome | Q37452154 | ||
| Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors. | Q37644973 | ||
| Re-examining class-I presentation and the DRiP hypothesis | Q37702916 | ||
| The nature and extent of contributions by defective ribosome products to the HLA peptidome. | Q37725183 | ||
| Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. | Q38817737 | ||
| Bromodomain inhibitors and cancer therapy: From structures to applications | Q39027056 | ||
| Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. | Q39067631 | ||
| Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands. | Q40264818 | ||
| Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells | Q41190385 | ||
| Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. | Q42775768 | ||
| The cleavage preference of the proteasome governs the yield of antigenic peptides. | Q42943174 | ||
| Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. | Q44783246 | ||
| 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization | Q45718710 | ||
| Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding | Q46469492 | ||
| Gapped sequence alignment using artificial neural networks: application to the MHC class I system. | Q47601200 | ||
| Acute Pharmacologic Degradation of a Stable Antigen Enhances Its Direct Presentation on MHC Class I Molecules | Q47718257 | ||
| Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation. | Q48000406 | ||
| Selective inhibition of BET bromodomains | Q24301009 | ||
| The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides | Q24339477 | ||
| Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method | Q24815448 | ||
| Drugging the undruggables: exploring the ubiquitin system for drug development | Q26752823 | ||
| BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 | ||
| Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules | Q28248180 | ||
| Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation | Q30002365 | ||
| Systems-wide temporal proteomic profiling in glucose-starved Bacillus subtilis | Q30500770 | ||
| PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements | Q31145457 | ||
| Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. | Q31151998 | ||
| Visual account of protein investment in cellular functions | Q33767436 | ||
| Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation | Q34083015 | ||
| Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. | Q34276766 | ||
| Large-scale gene function analysis with the PANTHER classification system | Q34358449 | ||
| Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer | Q34416771 | ||
| Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. | Q34478968 | ||
| Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. | Q34479551 | ||
| Catalytic in vivo protein knockdown by small-molecule PROTACs. | Q34480735 | ||
| Protein degradation and the generation of MHC class I-presented peptides. | Q34700398 | ||
| The immune epitope database (IEDB) 3.0. | Q35254745 | ||
| Soluble T-cell receptors produced in human cells for targeted delivery. | Q35602230 | ||
| The proteasome and MHC class I antigen processing | Q35967572 | ||
| Mechanisms of MHC class I-restricted antigen processing and cross-presentation | Q36266466 | ||
| Structural basis of PROTAC cooperative recognition for selective protein degradation | Q36306106 | ||
| NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets | Q36742441 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2697 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Specific MHC-I Peptides Are Induced Using PROTACs | |
| P478 | volume | 9 |
| Q96019158 | PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics |
| Q102371561 | Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti-tumor immunity in non-small cell lung cancer |
Search more.